Riboscience LLC
Biotech · Private
ENPP1 inhibitor small molecules for cancer immunotherapy, including lead compound RBS2418
- Grants
- $9.3M
- 8 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 40
- 12 granted · 28 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20172019202120232025
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase II · Advancing a novel potent Zika virus specific nucleoside analog to the clinic | $2,983,803 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase II · Advancing a novel potent Zika virus specific nucleoside analog to the clinic | $993,605 | |
| Federal grant | Department of Health and Human Services · Phase II · Advancing a novel potent Zika virus specific nucleoside analog to the clinic | $995,099 | |
| Federal grant | Department of Health and Human Services · Phase II · Advancing a novel potent Zika virus specific nucleoside analog to the clinic | $995,099 | |
| Federal grant | Department of Health and Human Services · Phase II · Advancing a novel potent double anti-HCV nucleoside analog combination treatment for the OUD population to the clinic | $995,102 | |
| Federal grant | Department of Health and Human Services · Phase II · Advancing a novel potent double anti-HCV nucleoside analog combination treatment for the OUD population to the clinic | $995,102 | |
| Federal grant | Department of Health and Human Services · Phase II · Advancing a novel potent double anti-HCV nucleoside analog combination treatment for the OUD population to the clinic | $995,102 | |
| Federal grant | Department of Health and Human Services · Phase I · Inhibitors of ENPP1 for the treatment of hepatocellular carcinoma | $306,739 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2999 | Tolerance Bio Inc. | — | $15M |
| 3000 | IMMUNOBLUE, LLC | — | — |
| 3001 | SOUVIE BIODELIVERY LLC | — | — |
| 3002 | Riboscience LLC | — | — |
| 3003 | AAIIT LLC | — | — |
| 3004 | Structure Therapeutics | — | — |
| 3005 | Provivi Inc. | — | $77M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Quinazoline Derivatives As Ectonucleotide Pyrophosphatase Phosphodiesterase 1 Inhibitorsapplication
- 7-AZA Bicyclic Heteroaryl Derivatives As Ectonucleotide Pyrophosphatase Phosphodiesterase 1 Inhibitorsapplication
- Bicyclic Heteroaryl Derivatives As Ectonucleotide Pyrophosphatase Phosphodiesterase 1 Inhibitorsapplication
- Bicyclic Heteroaryl Derivatives As Ectonucleotide Pyrophosphatase Phosphodiesterase 1 Inhibitorsgranted
- Bicyclic Heteroaryl Boronate Derivatives As Ectonucleotide Pyrophosphatase Phosphodiesterase 1 Inhibitorsapplication
- Bicyclic Heteroaryl Phosphonate Derivatives As Ectonucleotide Pyrophosphatase Phosphodiesterase 1 Inhibitorsapplication
- 4'-FLUORO-2'-METHYL Substituted Nucleoside Derivatives As Inhibitors Of Hcv Rna Replicationgranted
- Quinazoline Derivatives As Ectonucleotide Pyrophosphatase Phosphodiesterase 1 Inhibitorsapplication
- 4'-Fluoro-2'-Methyl Substituted Nucleoside Derivatives as Inhibitors of HCV RNA Replicationapplication
- 4'-Fluoro-2'-Methyl Substituted Nucleoside Derivatives as Inhibitors of HCV RNA Replicationgranted
- 4'-FLUORO-2'-METHYL Substituted Nucleoside Derivatives As Inhibitors Of Hcv Rna Replicationgranted
- 4'-VINYL Substituted Nucleoside Derivatives As Inhibitors Of Respiratory Syncytial Virus Rna Replicationgranted
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.